Medifocus Announces Institutional Review Board (IRB) Approval for Its Phase III Pivotal Breast Cancer Treatment Study  
10/20/2010 10:31:35 AM

COLUMBIA, Md.--(BUSINESS WIRE)--Medifocus Inc. (OTC:MDFZF.PK and TSXV:MFS) is pleased to announce that the University of Oklahoma Health Sciences Center’s Institutional Review Board (IRB) has granted final approval to conduct Medifocus’ Pivotal Phase III Breast Cancer Treatment Study at the University of Oklahoma Breast Institute, in Oklahoma City, under the supervision of William C. Dooley, M.D. the Principal Investigator for the Food and Drug Administration (FDA) approved study.